Trial Profile
A trial of fingolimod for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Feb 2016
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- 19 Feb 2016 New trial record